ETON
Eton Pharmaceuticals Inc
54.80$
-0.2%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | -100.0% | – | – | -78.4% | -79.8% | -905.0% | – | +14,587.7% | -74.2% | -74.7% | +686.2% | -64.3% | +238.1% | -56.3% | +164.0% | -37.6% | +126.2% | -41.4% | +4.1% | +8.9% | +13.9% | +13.8% | +12.8% | +48.4% | +9.5% | +18.7% | -5.2% | +14.0% | +54.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | -77.5% | -72.5% | -614.3% | – | +430.0% | -91.4% | +353.7% | -54.6% | +156.4% | +282.3% | -56.2% | +78.0% | -8.4% | +18.2% | +13.4% | +40.3% | -19.7% | +16.5% | +16.6% | +28.6% | +43.5% | -5.6% | +108.5% | -44.0% | +16.5% | +27.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | -150.0% | – | – | – | – | -71.6% | -94.6% | +3,579.1% | -74.9% | +216.4% | -56.3% | +215.2% | -47.4% | +189.4% | -54.5% | -17.6% | +37.9% | +12.4% | +12.0% | +2.8% | +52.3% | +20.9% | -34.1% | +66.8% | +12.5% | +72.5% | – | |
| – | +4.1% | +80.8% | -55.0% | +34.0% | -9.5% | -28.6% | +486.7% | -77.7% | +137.5% | -93.2% | +2,590.1% | -74.3% | +75.6% | +20.3% | -73.9% | +124.6% | +34.6% | -74.6% | +137.6% | -57.4% | +7.8% | +26.9% | -43.3% | +110.3% | -45.3% | +70.2% | -37.8% | +356.2% | -83.0% | +72.5% | +33.3% | +219.7% | -70.0% | +60.1% | +5.3% | -47.0% | – | |
| – | +77.1% | +144.0% | -42.6% | -41.4% | -16.2% | +42.7% | +34.2% | +20.2% | -15.0% | +49.6% | +7.5% | +11.9% | +17.4% | +10.8% | +6.8% | -19.5% | +1.9% | +14.8% | +29.0% | +6.8% | -20.8% | +4.4% | +22.8% | -12.6% | -7.2% | +5.5% | +12.7% | +8.4% | -5.4% | +27.0% | +36.5% | +5.6% | -16.3% | +9.3% | +18.0% | +11.3% | – | |
| – | +26.8% | +109.1% | -48.8% | -9.0% | -12.0% | -3.7% | +252.3% | -58.4% | +50.6% | -47.2% | +233.5% | -49.0% | +38.1% | +15.1% | -31.3% | +6.3% | +14.3% | -25.1% | +45.5% | -9.0% | -17.5% | +7.8% | +11.0% | -1.4% | -14.6% | +13.6% | +3.3% | +47.4% | -32.3% | +0.9% | +76.7% | +29.7% | -31.2% | +15.4% | +15.8% | +2.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -143.4% | – | – | -487.1% | – | – | – | -338.6% | – | -114.1% | – | – | – | – | +23.6% | -174.7% | – | – | – | -2.0% | +430.0% | – | |
| – | – | -100.0% | – | -3.4% | -10.7% | +228.0% | +75.6% | -30.6% | -23.0% | -48.1% | +320.0% | +14.3% | +20.8% | +15.9% | -8.2% | -4.0% | +4.2% | +11.3% | -11.6% | -10.3% | -31.2% | +70.7% | -50.8% | -1.6% | -75.0% | +1,064.5% | -97.0% | +372.7% | -84.6% | +16,562.5% | -12.8% | +3.0% | +1.2% | -0.3% | -30.5% | +28.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -139.4% | – | – | -613.0% | – | – | – | -391.7% | – | -112.7% | – | – | – | – | -202.0% | – | – | – | – | +11.3% | +644.5% | – | |
| – | – | – | -96.3% | +613.0% | +89.4% | +98.1% | -100.0% | – | – | – | – | – | – | – | – | – | – | +6,775.0% | -11.6% | -10.3% | -31.2% | -168.0% | – | +182.9% | -66.1% | +2.2% | -15.5% | -74.1% | -333.3% | – | -14.9% | -10.8% | -142.4% | – | – | +600.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -139.4% | – | – | -613.0% | – | – | – | -391.7% | – | -112.7% | – | – | – | – | -195.4% | – | – | – | – | +4.8% | +645.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -130.7% | – | – | -438.1% | – | – | – | -263.5% | – | -107.4% | – | – | – | – | -119.8% | – | -146.6% | – | +1,268.0% | -48.7% | +660.3% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.